Trial
NCT00913913
Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Dartmouth-Hitchcock Medical Center
Collaborators
National Cancer Institute (NCI)
Condition
Metastatic Renal Cell Carcinoma
Intervention
DC vaccine
Why stopped
low accrual not allowing site to meeting statistical endpoints
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-12-01